← All trials
NCT00532194
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2007
- Primary completion
- Apr 1, 2013
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 486
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Medical Research CouncilLead sponsor
- National Health and Medical Research Council, AustraliaCollaborator
- Australia New Zealand Gynaecological Oncology GroupCollaborator
- University of LondonOverall official - principal investigator
- Cancer Research UKCollaborator
- Grupo Español de Investigación en Cáncer de OvarioCollaborator
- AstraZenecaCollaborator
- Canadian Cancer Trials GroupCollaborator
- Medical Research CouncilReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.